Head-to-head trial compares weight loss drugs
- Details
- Category: Research
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs. In the 72-week trial - led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian and conducted with the University of Texas McGovern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin and Eli Lilly
New research offers hope for diabetic neuropathy sufferers
- Details
- Category: Research
A phenomenon largely ignored since its discovery 100 years ago appears to be a crucial component of diabetic pain, according to new research from The University of Texas at Dallas' Center for Advanced Pain Studies (CAPS).
Findings from a new study, published in Nature Communications, suggest that cell clusters called Nageotte nodules are a strong indicator of nerve cell death in human sensory ganglia.
Drug to slow Alzheimer's well tolerated outside of clinical trial setting
- Details
- Category: Research
The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease. But side effects - brain swelling and bleeding - emerged during clinical trials that have left some patients and physicians hesitant about the treatment.
HER3 re-emerges as a pivotal target in the fight against cancer
- Details
- Category: Research
A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy. Once considered a passive player due to its weak kinase activity, HER3 is now recognized as a major contributor to the survival and spread of various solid tumors, including breast, lung, colorectal, pancreatic, and gynecologic cancers.
Mitochondrial DNA editing: A breakthrough in tackling neurodegenerative diseases
- Details
- Category: Research
Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs). As these diseases continue to impose a significant global health burden, the innovative use of mitochondrial gene editing offers a promising avenue to address their underlying causes. The dysfunction of mitochondria, triggered by mutations in mtDNA, is now recognized as a pivotal factor contributing to the development of several debilitating conditions,
Diabetes drug as a possible treatment for prostate cancer
- Details
- Category: Research
An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is central to the regulation of metabolic processes, can also influence the growth of prostate cancer cells. PPARγ is already known to be a target of certain drugs used to treat type 2 diabetes.
Discovery explains Long COVID breathing problems
- Details
- Category: Research
Groundbreaking research from the University of Virginia School of Medicine has revealed crucial new insights into the immune systems of COVID-19 survivors, particularly those struggling with persistent breathing issues. The study shows that these patients have distinct changes in their immune system that link to the severity of their lung damage. This discovery holds promise for developing targeted treatments for the lung complications of Long COVID.
More Pharma News ...
- Harnessing generative AI to expand the mitochondrial targeting toolkit
- Shingles vaccine lowers the risk of heart disease for up to eight years
- New technology facilitates delivery of advanced medicines
- A candidate drug dismantles a metabolic barrier to anti-tumor immunity
- Fungi dwelling on human skin may provide new antibiotics
- Unlocking a new era in liver cancer treatment: The power of neddylation-targeted therapies
- Scientists finally confirm vitamin B1 hypothesis from 1958